An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Won, Eunsoo | - |
dc.contributor.author | Kim, Yong-Ku | - |
dc.date.accessioned | 2021-09-02T22:19:38Z | - |
dc.date.available | 2021-09-02T22:19:38Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81326 | - |
dc.description.abstract | Lithium has been used for the treatment of bipolar disorder (BD) for the last sixty or more years, and recent studies with more reliable designs and updated guidelines have recommended lithium to be the treatment of choice for acute manic, mixed and depressive episodes of BD, along with long-term prophylaxis. Lithium's specific mechanism of action in mood regulation is progressively being clarified, such as the direct inhibition on glycogen synthase kinase 3 beta, and its various effects on neurotrophic factors, neurotransmitters, oxidative metabolism, apoptosis, second messenger systems, and biological systems are also being revealed. Furthermore, lithium has been proposed to exert its treatment effects through mechanisms associated with neuronal plasticity. In this review, we have overviewed the clinical aspects of lithium use for BD, and have focused on the neuroprotective and neurotrophic effects of lithium. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | GLYCOGEN-SYNTHASE KINASE-3-BETA | - |
dc.subject | MAGNETIC-RESONANCE-SPECTROSCOPY | - |
dc.subject | GRAY-MATTER VOLUMES | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | I DISORDER | - |
dc.subject | MOOD DISORDERS | - |
dc.subject | MAINTENANCE TREATMENT | - |
dc.subject | DEPRESSIVE DISORDER | - |
dc.subject | HIPPOCAMPAL VOLUMES | - |
dc.subject | PSYCHOTIC SYMPTOMS | - |
dc.title | An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Ku | - |
dc.identifier.doi | 10.3390/ijms18122679 | - |
dc.identifier.scopusid | 2-s2.0-85037849541 | - |
dc.identifier.wosid | 000418896700182 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.18, no.12 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.volume | 18 | - |
dc.citation.number | 12 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | GLYCOGEN-SYNTHASE KINASE-3-BETA | - |
dc.subject.keywordPlus | MAGNETIC-RESONANCE-SPECTROSCOPY | - |
dc.subject.keywordPlus | GRAY-MATTER VOLUMES | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | I DISORDER | - |
dc.subject.keywordPlus | MOOD DISORDERS | - |
dc.subject.keywordPlus | MAINTENANCE TREATMENT | - |
dc.subject.keywordPlus | DEPRESSIVE DISORDER | - |
dc.subject.keywordPlus | HIPPOCAMPAL VOLUMES | - |
dc.subject.keywordPlus | PSYCHOTIC SYMPTOMS | - |
dc.subject.keywordAuthor | lithium | - |
dc.subject.keywordAuthor | bipolar disorder | - |
dc.subject.keywordAuthor | therapeutic mechanism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.